방사성 요오드 저항성 갑상선암에서 수술적 치료의 역할

• 영문명: Surgical Methods for Radioiodine Refractory Thyroid Cancer
• 발행기관: 대한내분비외과학회
• 저자명: 서수한¹ 이정훈² 소의영² Su Han Seo¹ Jung Hun Lee² and Euy Young Soh²
• 간행물 정보: 『The Koreran journal of Endocrine Surgery』13권1호, 1~7쪽, 전체 7쪽
• 주제분류: 의약학 > 일반외과학
• 파일형태: PDF
• 발행일자: 2013.03.30

영문 초록

Most patients with thyroid cancer (of follicular cell origin) are successfully managed with a combination of surgery, radioactive iodine (¹³¹I-RAI), and suppression of thyroid-stimulating hormone with thyroid hormone replacement, obtaining survival rates approaching 90% at 20 years. Although the prognosis of patients with differentiated thyroid carcinoma (DTC) is favorable, recurrence occurs in up to 30% patients. In addition, many patients with recurrent or metastatic disease, as well as those with less differentiated tumors, will have a much poorer prognosis and lose their ability to concentrate functional iodine and are therefore not targeted by ¹³¹I-RAI therapy. There are many treatment options but no definitive treatment for radioiodine refractory thyroid cancer. This paper will discuss the roles of surgical treatment for patients with radioiodine refractory thyroid cancer.

키워드

방사성 요오드 저항성 갑상선암, 수술,Radioactive iodine refractory thyroid cancer, Surgery